DC Field | Value | Language |
---|---|---|
dc.contributor.author | B I Yoo | - |
dc.contributor.author | K B Ahan | - |
dc.contributor.author | M H Kang | - |
dc.contributor.author | O S Kwon | - |
dc.contributor.author | Young-Soo Hong | - |
dc.contributor.author | Jung Joon Lee | - |
dc.contributor.author | H S Lee | - |
dc.contributor.author | J S Ryu | - |
dc.contributor.author | T Y Kim | - |
dc.contributor.author | D C Moon | - |
dc.contributor.author | S Song | - |
dc.contributor.author | Y B Chung | - |
dc.date.accessioned | 2017-04-19T09:02:58Z | - |
dc.date.available | 2017-04-19T09:02:58Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.uri | 10.1007/BF02977679 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/6997 | - |
dc.description.abstract | We investigated the pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after intravenous (i.v.) bolus administration at a multiple dose every 24 h for 5 days in rats. To analyze ID-6105 levels in biological samples, we used an HPLC-based method which was validated in a pharmacokinetic study by suitable criteria. The concentrations of ID-6105 after the multiple administration for 5 days were not significantly different from the results after the single administration. The t1/2α, t 1/2β, Vdss, and CLt after the multiple administration were not significantly different from the values after the single administration. Moreover, the concentrations of ID-6105 1 min at day 1-5 after i.v. bolus multiple administration did not show the significant difference. of the various tissues, ID-6105 mainly distributed to the kidney, lung, spleen, adrenal gland, and liver after i.v. bolus multiple administration. ID-6105 concentrations in the kidney or lung 2 h after i.v. bolus administration were comparable to the plasma concentration shortly after i.v. bolus administration. However, the ID-6105 concentrations in various tissues 48 h after i.v. bolus administration decreased to low levels. ID-6105 was excreted largely in the bile after i.v. bolus multiple administration at the dose of 3 mg/kg. The amounts of ID-6105 found in the bile by 12 h or in the urine by 48 h after the administration were calculated to be 14.1% or 4.55% of the initial dose, respectively, indicating that ID-6105 is mostly excreted in the bile. In conclusion, ID-6105 was rapidly cleared from the blood and transferred to tissues, suggesting that ID-6105 might not be accumulated in the blood following i.v. bolus multiple dosages of 3 mg/kg every 24 h for 5 days. By 48 h after i.v. bolus administration, ID-6105 concentrations in various tissues had decreased to very low levels. The majority of ID-6105 appears to be excreted in the bile. | - |
dc.publisher | Pharmaceutical Soc Korea | - |
dc.title | Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats | - |
dc.title.alternative | Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats | - |
dc.type | Article | - |
dc.citation.title | Archives of Pharmacal Research | - |
dc.citation.number | 4 | - |
dc.citation.endPage | 482 | - |
dc.citation.startPage | 476 | - |
dc.citation.volume | 28 | - |
dc.contributor.affiliatedAuthor | Young-Soo Hong | - |
dc.contributor.affiliatedAuthor | Jung Joon Lee | - |
dc.contributor.alternativeName | 유보임 | - |
dc.contributor.alternativeName | 안광복 | - |
dc.contributor.alternativeName | 강민희 | - |
dc.contributor.alternativeName | 권오승 | - |
dc.contributor.alternativeName | 홍영수 | - |
dc.contributor.alternativeName | 이정준 | - |
dc.contributor.alternativeName | 이홍섭 | - |
dc.contributor.alternativeName | 류정수 | - |
dc.contributor.alternativeName | 김태용 | - |
dc.contributor.alternativeName | 문동철 | - |
dc.contributor.alternativeName | 송석길 | - |
dc.contributor.alternativeName | 정윤복 | - |
dc.identifier.bibliographicCitation | Archives of Pharmacal Research, vol. 28, no. 4, pp. 476-482 | - |
dc.identifier.doi | 10.1007/BF02977679 | - |
dc.subject.keyword | 11-Hydroxyaclacinomycin X (ID-6105) | - |
dc.subject.keyword | Excretion | - |
dc.subject.keyword | Multiple administration | - |
dc.subject.keyword | Pharmacokinetics | - |
dc.subject.keyword | Tissue distribution | - |
dc.subject.local | 11-Hydroxyaclacinomycin X (ID-6105) | - |
dc.subject.local | Excretion | - |
dc.subject.local | excretion | - |
dc.subject.local | Multiple administration | - |
dc.subject.local | pharmacokinetics | - |
dc.subject.local | Pharmacokinetics | - |
dc.subject.local | Tissue distribution | - |
dc.subject.local | tissue distribution | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.